



EpiCARE

Research calls

Dear all,

We are glad to share the **current research calls**, carefully selected for you by the EpiCARE Research Council. You can read more information about the new funding opportunities on the [research council](#) webpage.

If you need help to answer a call and/or build a project with other EpiCARE members, do not hesitate to contact **EpiCARE Research manager**, [Sébile Tchaicha](#).

1. EJPRD Research Mobility Fellowships.

Deadline: November 13th, 2022

The call for Research Mobility Fellowships aims to support PhD students, Postdocs and medical doctors in training to undertake scientific visits fostering specialist research training outside their countries of residence.

The exchange can be carried out either:

- within the same ERN (Full Members and Affiliated Partners), OR
- between different ERNs (Full Members and Affiliated Partners), OR
- between ERN Full Members / Affiliated Partners and non-ERN institutions.

Training must be completed until **31.12.2023**

Travel up to 400 € for the entire fellowship (one single return ticket) and accommodation expenses up to 2.000 € per month will be covered for a fellowship with a duration of up to 6 months. Please note that the costs covered by fellowship have to be financed in advance by the fellows and will be reimbursed against receipt up to a fixed limit as set out in the documentation.

[More information](#)

2. CURE EPILEPSY - Rare Epilepsy Partnership Award

Rare Epilepsy Partnership Award (1 year / \$100,000) will support the development of necessary research tools, techniques, model systems, and data collection platforms to stimulate and accelerate research on rare epilepsies. Each award will be co-funded by CURE Epilepsy and one or more of the rare epilepsy advocacy groups (partners) identified in the Request For Proposals. Applications must focus on one or more of the specific rare epilepsies that are represented by each group as well as address CURE Epilepsy's mission to cure epilepsy.

[Link](#)

Registration Form Opens: Monday, January 16, 2023
Registration Form Submission Deadline: Wednesday, February 25, 2023
Selected Partners Informed: Wednesday, March 1, 2023
Request for Proposals Opens: Tuesday, May 30, 2023
Letter of Intent Deadline: Monday, June 26, 2023
Full Application Invitations: Monday, August 7, 2023
Full Application Deadline: Wednesday, September 13, 2023
Awardee Notification: December 2023-January 2024
Anticipated Award Start Date: Spring 2024

3. MSCA Staff Exchanges 2022

HORIZON-MSCA-2022-SE-01

Deadline: 8 Mar 2023

Indicative budget: 77.5 EUR million

The SE action funds short-term international and inter-sectoral exchanges of staff members involved in research and innovation activities of participating organisations. The aim is to develop sustainable collaborative projects between different organisations from the academic and non-academic sectors (in particular SMEs), based in Europe and beyond. Exchanged staff benefit from new knowledge, skills and career development perspectives, while participating organisations increase their research and innovation capacities.

Who can apply for Staff Exchanges?

Staff Exchanges are open to international consortia of universities, research institutions, businesses, SMEs and other non-academic organisations. They need to include at least three organisations in three different countries, two of which need to be located in a different EU Member State or Horizon Europe Associated Country above this minimum, the participation of organisations from any country is possible if all participating organisations are from the same sector (academic or non-academic), at least one must be from a non-associated Third Country

What does the funding cover?

Staff Exchanges projects can last up to four years. The grant funds the mobility of seconded staff members from one month to one year. Staff involved should return to their sending organisations after the secondment, to pass on their knowledge.

4. ERC Consolidator Grant

Deadline: 2 Feb 2023

Indicative budget: 2 EUR million for a period of 5 years. However, an additional € 1 million can be made available to cover eligible “start-up” costs for researchers moving from a third country to the EU or an associated country and/or the purchase of major equipment and/or access to large facilities and/or other major experimental and field work costs.

Are you a scientist who wants to consolidate your independence by establishing a research team and continuing to develop a success career in Europe? The ERC Consolidator Grant could be for you. You can also apply if you have recently created an independent, excellent research team and want to strengthen it.

Who can apply?

Researchers of any nationality with 7-12 years of experience since completion of PhD (Extensions are possible under certain circumstances)

[More information](#)

5.ERC Advanced Grant

Deadline: 23 May 2023

Indicative budget: € 2.5 million for a period of 5 years. However, an additional € 1 million can be made available to cover eligible “start-up” costs for researchers moving from a third country to the EU or an associated country and/or the purchase of major equipment and/or access to large facilities and/or other major experimental and field work costs.

Are you an established, leading principal investigator who wants long-term funding to pursue a ground-breaking, high-risk project? The ERC Advanced Grant could be for you.

Who can apply?

Applicants for the ERC Advanced Grants - called Principal Investigators (PI) - are expected to be active researchers who have a track-record of significant research achievements in the last 10 years.

[More information](#)

6. Towards a holistic support to children and adolescents' health and care provisions in an increasingly digital society

HORIZON-HLTH-2024-STAYHLTH-01-02-two-stage

Deadline for submission (two stages)

September 19, 2023

April 11, 2024

Total budget: €30M

Budget per project: 8-10 M€

Objectives:

- To develop solutions that promote a healthy lifestyle solutions for children and adolescents to have a long-term impact by using digital technologies.
- Develop and integrate innovative, privacy preserving tools and technologies, such as (but not limited to) activity trackers, sensors, serious games, platforms and robotics, Massive Open Online Courses (MOOCs) in coordinated and integrated care models, to help children and adolescents lead healthy, active and social lifestyles, prevent diseases, as well as to better monitor and manage their physical, social and mental health.
- Involve SMEs, national and regional authorities, patient associations and all relevant stakeholders to improve the adoption of solutions in health systems
- Involve relevant "Human and Social Sciences" expertise in the design and conduct of the project

7. Personalised prevention of non-communicable diseases - addressing areas of unmet needs using multiple data sources

HORIZON-HLTH-2024-STAYHLTH-01-05-two-stage

Deadline for submission (two stages)

-September 19, 2023

-April 11, 2024

Total budget: €50M

Budget per project: 8- 12 M€

Objective:

- To develop personalized strategies for prevention of non-communicable diseases (use of computational approaches, algorithms machine learning AI)
- Enable understanding of areas of unmet need in the prevention of non-communicable diseases, opportunity to mechanisms, management of disease progression and relapse. disease progression and relapse.
- Design new or improved and ambitious policy and intervention options
- Designing holistic approaches that include several of the following aspects: genetic predisposition: genetic predisposition, metagenomics, epigenomics, microbiome, metabolomics, sleep disorders, large cohorts, molecular profiling, impact of lack of activity, new predictive biomarker candidates, nutrition and diet

8. Integrated, multi scale computational models of patient pathophysiology ('virtual twins') for personalized disease management

2023-TOOL 05 03

Deadline for submission (single stage): April 13, 2023

Total budget: €50M

Budget per project: 8-10 M€

Objective

- To consolidate existing virtual twin models to move towards an integrated digital twin, with the goal of accelerating translational research towards the more cost-effective development of new health technologies
- Develop multi-scale, multi-organ, dynamic, interoperable and modular computer
- capable of accurately simulating the pathophysiology of an individual patient, covering different anatomical scales.
- Implement proof-of-concept and feasibility studies in relevant end-user environments to validate the developed models.
- Involve relevant "Human and Social Sciences" expertise in the design and conduct of the of the project

9. Better integration and use of health related real world and research data, including genomics, for improved clinical outcomes

2023- TOOL 05 04

Deadline for submission (single stage): April 13, 2023

Total budget: €35M

Budget per project: 8-10 M€

Objective:

- Integration of health data from multiple sources (electronic patient records, genomics, medical imaging, laboratory and diagnostic results pathogen data, public registries and other clinical research data) by linking real-life and clinical data
- Exemplify the integration of data across multiple case studies within or across multiple medical fields. At least one of the case studies must use whole genome sequencing data.
- New approaches to assemble large, easily findable and lawfully accessible high-quality datasets integrating multiple types of health data leading to improved clinical outcomes (e.g. new care solutions, personalised disease management, advanced diagnostic tools)

- New techniques, support tools, mechanisms and modalities to enable RGPD compliant access to sensitive personal data and to enable their reuse
- Development of a data analytics platform applying distributed learning and artificial intelligence approaches to query and aggregate efficiently, effectively and securely data from multiple sources for multiple use cases (groups of diseases), to monitor patients' health status, analyse causal inference, support diagnosis and health policy-makers, and establish recommendations for patients and other stakeholders.

10. Modelling and simulation to address regulatory needs in the development of orphan and pediatric medicines

HORIZON-HLTH-2023-IND-06-04

Deadline for submission (single stage): April 13, 2023

Total budget: €25M

Budget per project: 4-6 M€

Objective:

- Development of various methods of modeling and simulation as tools to meet regulatory needs in the clinical development cycle of new products for rare and pediatric diseases
- Establish a multidisciplinary approach for assessing the utility of mature computational models, as tools for supporting the optimal design of innovative clinical trials for small populations and as fit-for-purpose solutions for enabling the regulatory scientific advice and marketing authorisation assessment of orphan and/or paediatric medicines, including their pharmacovigilance follow-up. Evaluate validated in silico models for their ability to increase statistical robustness, improve the assessment of the benefit/risk ratio in small populations, and for their accuracy in predicting and extrapolate therapeutic effects.
- Calibrate and optimise mature computational models for enhancing their clinical performance, by using relevant sources of patient data (e.g. natural history and observational clinical studies, medical records, registries, pharmacovigilance and longitudinal studies etc.). The models should include a variety of modelling methods and in particular hybrid solutions linking quantitative mechanistic modelling with advanced statistical modelling (e.g. quantitative systems pharmacology, disease mechanistic models, physiology-based pharmacodynamic/pharmacokinetic models, Bayesian modelling, artificial intelligence algorithms etc.).
- Assess validated in-silico models for their capability to increase the statistical robustness, improve the risk/benefit assessment in small population clinical trials, and for their accuracy to predict and extrapolate the therapeutic and dose effects, taking into account the patient's genotypes/phenotypes, disease characteristics/stage variables and/or clinical/surrogate endpoints for delivering robust evidence of safety and efficacy of the orphan and paediatric medicines under study.
- Benchmark of diverse computational models by showcasing their simulation performance in virtual patient cohorts and by demonstrating that the models' synthetic data estimates match to actual clinical trial data

11. Towards structuring brain health research in Europe

HORIZON-HLTH-2023-DISEASE-03-06

Deadline for submission (single stage): April 13, 2023

Budget: EUR 1.00 million

Proposals should address all of the following aspects:

- Develop a structured system of exchange of information between policy makers, funders, and other relevant bodies¹²⁸ in order to establish synergies and avoid duplication of efforts.
- The aim is to structure brain health research in Europe and pave the way for a possible future partnership.
- Develop a strategic research and innovation agenda, taking into account the efforts already undertaken by EU-supported actions. The strategic research and innovation agenda will identify a number of measurable, scientific-technological priorities and socio-economic objectives, supported by an appropriate analysis.
- Develop plans for a governance structure of a future partnership, as well as implementation modalities with long-term sustainability in mind, and under the leadership of an EU Member State or Associated Country.
- Ensure a broad geographical representation of European countries and plan for inclusion of all main related research initiatives, as well as key organisations and associations. In this way, the coordination action should reflect the ‘umbrella’ role of a future initiative that will structure brain health research in Europe, and make it more impactful.
- Consider international initiatives by engaging with global organisations, as well as with global initiatives and research organisations in the field.
- Elaborate on platforms and tools for use by the research community, including on how they can best complement, integrate with each other. In this context, infrastructures already developed at the European or national level that enable sharing of samples, quality data and advanced analytical tools should be included in the analysis. Reflections should also be made on how the future initiative can contribute to the development of the European Health Data Space.

12. European Partnership on Rare Diseases

HORIZON-HLTH-2023-DISEASE-07-01

Deadline for submission (single stage): September 19,2023

Budget: EUR 50.00 million.

The co-funded European Partnership on rare diseases should be implemented based on the priorities identified in the Strategic Research and Innovation Agenda and through a joint program of activities ranging from coordinating and funding transnational research to highly integrative and community-driven ‘in-house’ activities such as innovation strategies for the efficient exploitation of research results, EU clinical trial preparedness activities, optimization of research infrastructures and resources, including networking, training and dissemination activities. It should be structured along the following **main objectives**:

- Launch joint transnational calls for RD research and innovation priorities as defined in the Strategic Research and Innovation Agenda, resulting in financial support to third parties, based on the annual work plans;
- Develop a European Clinical Research Network to accelerate the clinical trial readiness of the RD research community in Europe, to improve the research and innovation potential of RD stakeholders and facilitate the cost-effective clinical development of new therapies;
- Develop and consolidate the capacity building of the RD data ecosystem by supporting the federated access/sharing of FAIR research data, information resources to ensure the effective and fast translation of the research results to safe and effective health innovations;
- Integrate basic, pre-clinical and clinical research to reduce the burden for people living with a rare disease.
- Support research in relevant medical fields and intervention areas (prevention, diagnosis, treatment), while improving the utilization of existing health technologies in clinical practice;
- Support the scientific work of the International Rare Disease Research Consortium.

13. Comparative effectiveness research for healthcare interventions in areas of high public

health need

HORIZON-HLTH-2024-DISEASE-03-08-two-stage

Deadline for submission (two stages): September 19, 2023 / April 11, 2024

Total budget: €45M

Budget per project: 6- 7 M€

Scope: Effective, affordable and accessible healthcare for diverse population groups is challenging and complex. For example, specific needs underlie the delivery of effective preventive actions and therapeutic treatments to a rapidly growing elderly population, often presenting comorbidities and associated poly-pharmacy. The pediatric population, including children born preterm, has also its specific needs in specially adjusted therapeutics and early.

Proposals should address most of the following:

- Compare the use of currently existing (pharmacological, non-pharmacological and technological) healthcare interventions in specific population groups (or selected subgroups). While there is no restriction on diseases or conditions, preference will be given to proposals focusing on interventions with high public health relevance.
- Ensure acceptability and sustainability of the healthcare intervention through early involvement of 'end users' (e.g. patients, care providers) in the design of the study (integrating patient valued outcomes) and, where possible, in the research process including implementation. Additionally, proposals should take into account the diversity of health systems in different regions of Europe to allow large-scale uptake.
- Consider involving HTA bodies in order to create synergies and accelerate the practical implementation of the results.
- Consider issues of particular relevance for the target populations, for example, multimorbidity, complex chronic conditions, poly-pharmacy, substance misuse, vaccine efficacy, compliance, age, gender specificities and diseases with high societal burden (including but not limited to e.g. musculoskeletal diseases and mental health disorders).

For the chosen population, assess clinical and safety parameters, as well as health and socio-economic outcomes (e.g. quality of life, patient mortality, (co)morbidity, costs, and performance of the health system). Agreed core outcome sets (COS) should be used as endpoints in conditions where they already exist, in other cases, efforts should be made to agree on such COS. Consider using new instruments and methods for determining the burden of disease and for evaluating the effects of the interventions. Low cost innovations should also be considered.

14. Tackling high-burden for patients, under-researched medical conditions

HORIZON-HLTH-2024-DISEASE-03-14-two-stage

Deadline for submission (two stages): September 19, 2023 / April 11, 2024

Total budget: €45M

Budget per project: 6- 7 M€

Scope: Effective, affordable and accessible healthcare for diverse population groups is challenging and complex. For example, specific needs underlie the delivery of effective preventive actions and therapeutic treatments to a rapidly growing elderly population, often presenting comorbidities and associated poly-pharmacy. The pediatric population, including children born preterm, has also its specific needs in specially adjusted therapeutics and early.

Proposals should address most of the following:

- Compare the use of currently existing (pharmacological, non-pharmacological and technological) healthcare interventions in specific population groups (or selected subgroups). While there is no restriction on diseases or conditions, preference will be given to proposals focusing on interventions with high public health relevance.
- Ensure acceptability and sustainability of the healthcare intervention through early involvement of 'end users' (e.g. patients, care providers) in the design of the study

(integrating patient valued outcomes) and, where possible, in the research process including implementation. Additionally, proposals should take into account the diversity of health systems in different regions of Europe to allow large-scale uptake.

- Consider involving HTA bodies in order to create synergies and accelerate the practical implementation of the results.
- Consider issues of particular relevance for the target populations, for example, multimorbidity, complex chronic conditions, poly-pharmacy, substance misuse, vaccine efficacy, compliance, age, gender specificities and diseases with high societal burden (including but not limited to e.g. musculoskeletal diseases and mental health disorders).

For the chosen population, assess clinical and safety parameters, as well as health and socio-economic outcomes (e.g. quality of life, patient mortality, (co)morbidity, costs, and performance of the health system). Agreed core outcome sets (COS) should be used as endpoints in conditions where they already exist, in other cases, efforts should be made to agree on such COS. Consider using new instruments and methods for determining the burden of disease and for evaluating the effects of the interventions. Low cost innovations should also be considered.

15. The Epilepsy Study Consortium Mini-grant

The Epilepsy Study Consortium is sponsoring a mini-grant of up to **\$22,000** for epilepsy fellows to undertake a mentored research project on anti-epileptic drug therapy during their fellowship training.

The award does not require past experience with research or a specific percent protected time for research but instead focuses on the mentorship and training experience for the fellow. Applicants may request funding periods of six months to one year.

Research must focus on anti-epileptic drug therapy. Clinical or basic science research may be proposed, and funds may be used to support a limited research project, or for the collection of preliminary data leading to a larger research effort.

Important Dates for Applicants

September 2022: Application submission opens through ProposalCentral

January 12, 2023: Full proposals due

May 2023: Award notifications sent out

July 1, 2023: Earliest award start date. Start may be delayed up to three months.

[More information on these calls](#)



European
Reference
Networks

Co-funded by the European Union



Our mailing address is:

Department of Paediatric Clinical Epileptology, Sleep Disorders and Functional Neurology
ERN EpiCARE c/o Pr Arzimanoglou
Hôpital Femme Mère Enfant (HFME)
59 Boulevard Pinel
69677 Bron, FRANCE

[Unsubscribe](#)

© 2021 EpiCARE All rights reserved.

You are receiving this email as you may work at one of the EpiCARE centres, or you are taking part in one or more of EpiCARE expert groups, or you may have attended one of our webinars.

[Having Trouble Viewing This Email? Open this newsletter in your browser](#)

© 2021 Hospices Civils de Lyon (ERN EpiCARE)